Basilea Snaps Up Another Antibiotics Program As Pipeline Swells

15 Jan 2024

The company has bagged a preclinical program from struggling Swiss biotech Spexis for $2.3m upfront, its fourth deal in as many months.

Swiss flag — 2024 looking promising for Switzerland's Basilea • Source: Shutterstock

After a busy 2023 on the business development front, Basilea Pharmaceutica Ltd. has started the year by adding more assets to its pipeline with the acquisition of a preclinical antibiotics program from fellow Swiss biotech Spexis AG.

Key Takeaways

Basilea has been restocking its pipeline through a number of deals

The acquired antibiotics are of a novel class, targeting lipopolysaccharide transport in Gram-negative bacteria, which have been highlighted by the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

24 Jul 2025

• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

23 Jul 2025

• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.